4-PrO-DMT

4-PrO-DMT
Clinical data
Other names	4-Propanoyloxy dmt
Identifiers
	IUPAC name [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] propanoate;
CAS Number	1373882-11-1;
PubChem CID	155907598;
ChemSpider	84400449;
UNII	B9BF25HPH4;
Chemical and physical data
Formula	C15H20N2O2
Molar mass	260.337 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)OC1=CC=CC2=C1C(=CN2)CCN(C)C;
	InChI InChI=1S/C15H20N2O2/c1-4-14(18)19-13-7-5-6-12-15(13)11(10-16-12)8-9-17(2)3/h5-7,10,16H,4,8-9H2,1-3H3; Key:KUOGXPDQORRHED-UHFFFAOYSA-N;

4-Propionoxy-N,N-dimethyltryptamine (4-PrO-DMT, or O-Propionylpsilocin) is a synthetic psychedelic drug from the tryptamine family with psychedelic effects, and is theorized to act as a prodrug for psilocin. It has been sold online as a designer drug since May 2019. It was first identified as a new psychoactive substance in Sweden, in July 2019.[1]

Recreational use

4-PrO-DMT Crystals

Dosage

4-PrO-DMT is reported to be orally active, though its threshold and duration are unstudied.

Effects

The effects of 4-PrO-DMT are broadly comparable to those of other serotonergic psychedelics such as LSD and psilocybin.

Pharmacology

Pharmacodynamics

4-PrO-DMT is theorized to be a serotonergic psychedelic, and is partial agonist of the 5-HT_1D, 5-HT_1B and 5-HT_1A serotonin receptors.

Similar to 4-AcO-DMT, 4-PrO-DMT is believed to be a pro-drug of psilocin.

Toxicity

Very little data about the toxicity or pharmacology of 4-PrO-DMT is known. Its chemical structure and pharmacological activity are similar to psilacetin, a compound which isn't associated with compulsive use or physical dependence. However, due to lack of research and data, it cannot be definitively concluded that its pharmacological actions in the human body do not differ from those of psilacetin. To date, there have been no reported deaths from 4-PrO-DMT.

References

European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584.